Featured Research

from universities, journals, and other organizations

Gel May Cut Doses For Some Medications

Date:
December 8, 2000
Source:
Purdue University
Summary:
A material invented at Purdue University is showing promise as a drug-delivery system that might replace some multiple-dose medications with a single daily formulation.

WEST LAFAYETTE, Ind. – A material invented at Purdue University is showing promise as a drug-delivery system that might replace some multiple-dose medications with a single daily formulation.

Kos Pharmaceuticals Inc. of Miami, Fla., has signed a license from the Purdue Research Foundation's Office of Technology Commercialization to develop the material for a "gastric-retention" drug-delivery system.

The material, called "superporous hydrogels," expands dramatically when immersed in water. Oral drug delivery formulations made from the gels would swell rapidly in the stomach, causing medications to move more slowly from the stomach to the intestines.

Because the medications would remain in the stomach longer, they would be absorbed more efficiently by the body. Such a system might make it possible to take certain medications only once daily, instead of three or more times a day, said Kinam Park, a professor of pharmaceutics and biomedical engineering at Purdue.

Unlike other gels being tested for drug delivery, the superporous hydrogels swell to hundreds of times their dehydrated form within a matter of seconds, said Park, the gels' inventor.

Conventional hydrogels of the same size take hours to expand. The new hydrogels' rapid expansion is possible because they are riddled with numerous, interconnected pores, each one about the width of a human hair. The pores act as capillaries to draw in water.

"When you swallow something into the stomach, unless it swells very fast, it is going to be emptied into the intestine rather quickly," said Park. "That's why we came up with the so-called superporous hydrogels for gastric-retention applications."

Formulation scientists at Kos Pharmaceuticals were impressed with the technology, said Daniel M. Bell, the company's president and chief executive officer.

"We believe it will extend the number of opportunities we can pursue in improving the formulations of certain existing products," Bell said.

Kos Pharmaceuticals has begun work to develop formulations that can be tested in humans. However, the company will not disclose specific product applications until clinical trials are underway.

The hydrogels are made from various types of polymers called acrylic polymers. But the nature of the polymer is far less important than the gels' porous structure. The pores are formed by using an effervescing agent that fizzes, producing bubbles as the polymer is being synthesized into hydrogels. The bubbles create the pore formation.

Park has been working on the material for 15 years. It has also been licensed to a medical device company called MicroVention Inc., of Aliso Viejo, Calif., for developing a method to treat aneurysms, Park said.

The promise of Park's hydrogels illustrates how the public benefits through university research, said Lisa Kuuttila, assistant vice president and director of the Purdue Office of Technology Commercialization.

Superporous hydrogels have other potential applications, including their possible use in controlling appetite. Because the hydrogels swell so dramatically in the stomach, they might be used to induce the feeling of being full, reducing hunger pangs, Park said.

Another possible use would be to make toys that expand when placed in water, he said. A toy made from conventional hydrogels would take a day or two to fully expand, compared with seconds for the superporous variety.

The U.S. Food and Drug Administration has not yet approved any potential uses for superporous hydrogels.


Story Source:

The above story is based on materials provided by Purdue University. Note: Materials may be edited for content and length.


Cite This Page:

Purdue University. "Gel May Cut Doses For Some Medications." ScienceDaily. ScienceDaily, 8 December 2000. <www.sciencedaily.com/releases/2000/11/001120074141.htm>.
Purdue University. (2000, December 8). Gel May Cut Doses For Some Medications. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2000/11/001120074141.htm
Purdue University. "Gel May Cut Doses For Some Medications." ScienceDaily. www.sciencedaily.com/releases/2000/11/001120074141.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins